Siemens Healthineers : A better Q4, FY 2022-23 guidance in the expected range, providing downside to consensus
>Strong performance in imaging drives Q4 - Q4 was better than we (by 3% on revenues, 10% on adj. EBIT) and consensus (by 3% and 4%, respectively) had expected. On revenues this was due to forex tailwinds (c.50% of the beat) and also to better comparable revenue growth of 6.8% y-o-y vs 5.9% y-o-y in our forecast and 5.5% y-o-y for the consensus. The beat on adjusted EBIT was due a strong margin in imaging (23.5% vs 20.2% in our forecast and 22.2% for the consensus). He...Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.